1. Home
  2. FATE vs CDLX Comparison

FATE vs CDLX Comparison

Compare FATE & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • CDLX
  • Stock Information
  • Founded
  • FATE 2007
  • CDLX 2008
  • Country
  • FATE United States
  • CDLX United States
  • Employees
  • FATE N/A
  • CDLX N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • CDLX Computer Software: Programming Data Processing
  • Sector
  • FATE Health Care
  • CDLX Technology
  • Exchange
  • FATE Nasdaq
  • CDLX Nasdaq
  • Market Cap
  • FATE 116.5M
  • CDLX 114.5M
  • IPO Year
  • FATE 2013
  • CDLX 2018
  • Fundamental
  • Price
  • FATE $1.47
  • CDLX $1.88
  • Analyst Decision
  • FATE Hold
  • CDLX Hold
  • Analyst Count
  • FATE 6
  • CDLX 3
  • Target Price
  • FATE $3.30
  • CDLX $2.25
  • AVG Volume (30 Days)
  • FATE 3.1M
  • CDLX 5.0M
  • Earning Date
  • FATE 11-11-2025
  • CDLX 11-05-2025
  • Dividend Yield
  • FATE N/A
  • CDLX N/A
  • EPS Growth
  • FATE N/A
  • CDLX N/A
  • EPS
  • FATE N/A
  • CDLX N/A
  • Revenue
  • FATE $8,470,000.00
  • CDLX $266,201,000.00
  • Revenue This Year
  • FATE N/A
  • CDLX N/A
  • Revenue Next Year
  • FATE N/A
  • CDLX N/A
  • P/E Ratio
  • FATE N/A
  • CDLX N/A
  • Revenue Growth
  • FATE N/A
  • CDLX N/A
  • 52 Week Low
  • FATE $0.66
  • CDLX $0.85
  • 52 Week High
  • FATE $3.50
  • CDLX $5.25
  • Technical
  • Relative Strength Index (RSI)
  • FATE 62.81
  • CDLX 47.63
  • Support Level
  • FATE $1.30
  • CDLX $1.82
  • Resistance Level
  • FATE $1.65
  • CDLX $2.20
  • Average True Range (ATR)
  • FATE 0.17
  • CDLX 0.23
  • MACD
  • FATE 0.02
  • CDLX -0.08
  • Stochastic Oscillator
  • FATE 73.77
  • CDLX 13.53

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About CDLX Cardlytics Inc.

Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K. and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.

Share on Social Networks: